Literature DB >> 28470469

Somatic mutations of calreticulin in myeloproliferative neoplasms.

Misa Imai1,2, Marito Araki3, Norio Komatsu4.   

Abstract

Recurrent somatic mutations in calreticulin (CALR) gene that encodes a molecular chaperone residing in the endoplasmic reticulum were identified in 2013 in a subset of patients with myeloproliferative neoplasms (MPNs). All of these mutations found in patients were either small insertion or deletion in a narrow region on exon 9 of CALR gene, and caused +1 frameshift in the reading frame for the translation of the carboxyl-terminus of CALR. Because of this unique feature, the CALR mutation is believed to be a gain-of-function mutation. However, there was essentially no rationale model to implicate the involvement of mutant CALR in the pathogenesis of MPN or other malignancies. Based on the recent findings, this review summarizes a novel molecular mechanism by which this mutant molecular chaperone constitutively activates the cytokine receptor to induce cellular transformation in MPNs.

Entities:  

Keywords:  Autocrine; Calreticulin; Chaperone; MPL; Myeloproliferative neoplasms; Thrombopoietin receptor

Mesh:

Substances:

Year:  2017        PMID: 28470469     DOI: 10.1007/s12185-017-2246-9

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  17 in total

1.  Endogenous megakaryocytic colonies underline association between megakaryocytes and calreticulin mutations in essential thrombocythemia.

Authors:  Julie Mondet; Ji-Hye Park; Audrey Menard; Christophe Marzac; Serge Carillo; Emmanuel Pourcelot; Francois Girodon; Xenia Cabagnols; Laurence Lodé; Nuria Socoro; Martine Chauvet; Claude-Eric Bulabois; Pascale Cony-Makhoul; Selim Corm; Jean-Yves Cahn; Pascal Mossuz
Journal:  Haematologica       Date:  2015-02-06       Impact factor: 9.941

Review 2.  The evolving genomic landscape of myeloproliferative neoplasms.

Authors:  Jyoti Nangalia; Tony R Green
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2014-11-18

3.  Somatic mutations of calreticulin in myeloproliferative neoplasms.

Authors:  Thorsten Klampfl; Heinz Gisslinger; Ashot S Harutyunyan; Harini Nivarthi; Elisa Rumi; Jelena D Milosevic; Nicole C C Them; Tiina Berg; Bettina Gisslinger; Daniela Pietra; Doris Chen; Gregory I Vladimer; Klaudia Bagienski; Chiara Milanesi; Ilaria Carola Casetti; Emanuela Sant'Antonio; Virginia Ferretti; Chiara Elena; Fiorella Schischlik; Ciara Cleary; Melanie Six; Martin Schalling; Andreas Schönegger; Christoph Bock; Luca Malcovati; Cristiana Pascutto; Giulio Superti-Furga; Mario Cazzola; Robert Kralovics
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245

4.  Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation.

Authors:  Shannon Elf; Nouran S Abdelfattah; Edwin Chen; Javier Perales-Patón; Emily A Rosen; Amy Ko; Fabian Peisker; Natalie Florescu; Silvia Giannini; Ofir Wolach; Elizabeth A Morgan; Zuzana Tothova; Julie-Aurore Losman; Rebekka K Schneider; Fatima Al-Shahrour; Ann Mullally
Journal:  Cancer Discov       Date:  2016-03-07       Impact factor: 39.397

5.  Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes.

Authors:  Chunaram Choudhary; Jesper V Olsen; Christian Brandts; Jürgen Cox; Pavankumar N G Reddy; Frank D Böhmer; Volker Gerke; Dirk-E Schmidt-Arras; Wolfgang E Berdel; Carsten Müller-Tidow; Matthias Mann; Hubert Serve
Journal:  Mol Cell       Date:  2009-10-23       Impact factor: 17.970

6.  Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis.

Authors:  Caroline Marty; Christian Pecquet; Harini Nivarthi; Mira El-Khoury; Ilyas Chachoua; Micheline Tulliez; Jean-Luc Villeval; Hana Raslova; Robert Kralovics; Stefan N Constantinescu; Isabelle Plo; William Vainchenker
Journal:  Blood       Date:  2015-11-25       Impact factor: 22.113

7.  Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms.

Authors:  Marito Araki; Yinjie Yang; Nami Masubuchi; Yumi Hironaka; Hiraku Takei; Soji Morishita; Yoshihisa Mizukami; Shin Kan; Shuichi Shirane; Yoko Edahiro; Yoshitaka Sunami; Akimichi Ohsaka; Norio Komatsu
Journal:  Blood       Date:  2016-01-27       Impact factor: 22.113

8.  Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants.

Authors:  Ilyas Chachoua; Christian Pecquet; Mira El-Khoury; Harini Nivarthi; Roxana-Irina Albu; Caroline Marty; Vitalina Gryshkova; Jean-Philippe Defour; Gaëlle Vertenoeil; Anna Ngo; Ann Koay; Hana Raslova; Pierre J Courtoy; Meng Ling Choong; Isabelle Plo; William Vainchenker; Robert Kralovics; Stefan N Constantinescu
Journal:  Blood       Date:  2015-12-14       Impact factor: 22.113

9.  Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib.

Authors:  K Shide; T Kameda; T Yamaji; M Sekine; N Inada; A Kamiunten; K Akizuki; K Nakamura; T Hidaka; Y Kubuki; H Shimoda; A Kitanaka; A Honda; A Sawaguchi; H Abe; T Miike; H Iwakiri; Y Tahara; M Sueta; S Hasuike; S Yamamoto; K Nagata; K Shimoda
Journal:  Leukemia       Date:  2016-11-03       Impact factor: 11.528

10.  Thrombopoietin receptor is required for the oncogenic function of CALR mutants.

Authors:  H Nivarthi; D Chen; C Cleary; B Kubesova; R Jäger; E Bogner; C Marty; C Pecquet; W Vainchenker; S N Constantinescu; R Kralovics
Journal:  Leukemia       Date:  2016-02-17       Impact factor: 11.528

View more
  9 in total

Review 1.  Concise Review: Advanced Cell Culture Models for Diamond Blackfan Anemia and Other Erythroid Disorders.

Authors:  Anna Rita Migliaccio; Lilian Varricchio
Journal:  Stem Cells       Date:  2017-12-05       Impact factor: 6.277

2.  Mutational subtypes of JAK2 and CALR correlate with different clinical features in Japanese patients with myeloproliferative neoplasms.

Authors:  Kyohei Misawa; Hajime Yasuda; Marito Araki; Tomonori Ochiai; Soji Morishita; Shuichi Shirane; Yoko Edahiro; Akihiko Gotoh; Akimichi Ohsaka; Norio Komatsu
Journal:  Int J Hematol       Date:  2018-02-20       Impact factor: 2.490

3.  Elevated plasma levels of procoagulant microparticles are a novel risk factor for thrombosis in patients with myeloproliferative neoplasms.

Authors:  Yasuhiro Taniguchi; Hirokazu Tanaka; Espinoza J Luis; Kazuko Sakai; Takahiro Kumode; Keigo Sano; Kentarou Serizawa; Shinya Rai; Yasuyoshi Morita; Hitoshi Hanamoto; Kazuo Tsubaki; Kazuto Nishio; Itaru Matsumura
Journal:  Int J Hematol       Date:  2017-08-05       Impact factor: 2.490

4.  Structural Analysis of Calreticulin, an Endoplasmic Reticulum-Resident Molecular Chaperone.

Authors:  Gunnar Houen; Peter Højrup; Evaldas Ciplys; Christine Gaboriaud; Rimantas Slibinskas
Journal:  Prog Mol Subcell Biol       Date:  2021

5.  Thrombohemorrhagic events, disease progression, and survival in polycythemia vera and essential thrombocythemia: a retrospective survey in Miyazaki prefecture, Japan.

Authors:  Ayako Kamiunten; Kotaro Shide; Takuro Kameda; Masaaki Sekine; Yoko Kubuki; Masafumi Ito; Takanori Toyama; Noriaki Kawano; Kousuke Marutsuka; Kouichi Maeda; Masanori Takeuchi; Hiroshi Kawano; Seiichi Sato; Junzo Ishizaki; Keiichi Akizuki; Yuki Tahira; Haruko Shimoda; Tomonori Hidaka; Kiyoshi Yamashita; Hitoshi Matsuoka; Kazuya Shimoda
Journal:  Int J Hematol       Date:  2018-02-27       Impact factor: 2.490

6.  Dexamethasone-Mediated Upregulation of Calreticulin Inhibits Primary Human Glioblastoma Dispersal Ex Vivo.

Authors:  Mohan Nair; Juan Romero; Aria Mahtabfar; Ahmed M Meleis; Ramsey A Foty; Siobhan A Corbett
Journal:  Int J Mol Sci       Date:  2018-02-14       Impact factor: 5.923

Review 7.  Focus on Osteosclerotic Progression in Primary Myelofibrosis.

Authors:  Mariarita Spampinato; Cesarina Giallongo; Alessandra Romano; Lucia Longhitano; Enrico La Spina; Roberto Avola; Grazia Scandura; Ilaria Dulcamare; Vincenzo Bramanti; Michelino Di Rosa; Nunzio Vicario; Rosalba Parenti; Giovanni Li Volti; Daniele Tibullo; Giuseppe A Palumbo
Journal:  Biomolecules       Date:  2021-01-19

8.  Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2.

Authors:  Jing Yang; Ellen L Weisberg; Xiaoxi Liu; Robert S Magin; Wai Cheung Chan; Bin Hu; Nathan J Schauer; Shengzhe Zhang; Ilaria Lamberto; Laura Doherty; Chengcheng Meng; Martin Sattler; Lucia Cabal-Hierro; Eric Winer; Richard Stone; Jarrod A Marto; James D Griffin; Sara J Buhrlage
Journal:  Leukemia       Date:  2021-07-29       Impact factor: 11.528

9.  ASXL1 mutations in Chinese patients with essential thrombocythemia.

Authors:  Yan-Bo Nie; Meng Sun; Colin K He; Man-Kai Ju; Fu-Ling Zhou; San-Yun Wu; Yi Zhou; Li Liu; Hui Shen; Ting-Ting Huang; Pan Liu; Ying Xu; Liang Shao; Xue-Lan Zuo
Journal:  Exp Ther Med       Date:  2018-03-09       Impact factor: 2.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.